Home · World · May 5 archive
German biotechnology company BioNTech announces it will halt production of its COVID-19 vaccine due to drastic restructuring plans, leaving sole production of the vaccine to its pa
Developing
In Short: German biotechnology company BioNTech, which gained global recognition for its work on one of the first mRNA coronavirus vaccines, has announced it will halt production of its COVID-19 vaccine in Germany due to drastic restructuring plans.
German biotechnology company BioNTech, which gained global recognition for its work on one of the first mRNA coronavirus vaccines, has announced it will halt production of its COVID-19 vaccine in Germany due to drastic restructuring plans.
The company, based in Mainz, stated that it will produce the last doses of the vaccine in Germany this year, with sole production to be handled by its partner Pfizer.
BioNTech had announced plans to cut between 950 and 1,350 full-time jobs over the next two years, responding to a significant drop in demand for COVID-19 vaccines.
In March, BioNTech's founders, Ugur Sahin and Özlem Türeci, announced their departure to launch a new venture, further signaling the company's shift in focus.
What's confirmed
What's still developing
- The Mainz-based company BioNTech that shot to global notoriety amid the COVID-19 pandemic for its work on one of the first mRNA coronavirus vaccines has announced drastic restructuring plans.
- "In the course of this year we will produce the last doses here in Germany," a company spokeswoman told the Reuters news agency.
- BioNTech said last year that it would be cutting between 950 and 1,350 full time jobs over the subsequent two years — it's not clear how many it had already cut.
- BioNTech said that it was reacting to a marked decline in demand for COVID vaccines.
- BioNTech's founders Ugur Sahin and Özlem Türeci announced in March that they were stepping down to start a new venture.
Sources
- DWlink